Products
Dornase alfa is commercially available as an inhalation solution (Pulmozyme). It has been approved in many countries since 1994.
Structure and properties
Dornase alfa is a genetically engineered variant of the enzyme human deoxyribonuclease I, which occurs naturally in humans.
Effects
Dornase alfa (ATC R05CB13) has mucolytic properties. It cleaves extracellular DNA in the respiratory tract. The DNA is released from disintegrating leukocytes, thereby increasing the viscosity of mucus and sputum. The drug can be used to reduce the viscosity of mucus and improve lung function.
Indications
For the treatment of cystic fibrosis in combination with standard therapy.
Dosage
According to the SmPC. The solution is inhaled once or twice daily with a nebulizer.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Interactions
Standard medications for the treatment of cystic fibrosis may be combined with dornase alfa. However, the inhalation solution should not be mixed with other medications.
Adverse effects
Possible adverse effects include conjunctivitis, voice disorders, inflammation of the pharynx, larynx, and nasal mucosa, dyspepsia, rash, hives, chest pain, and fever.
